Table 4 Cell culture studies demonstrating that vorinostat enhances the antitumour efficacy of radiation therapy or chemotherapy

From: Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor

Study

Combination

Cell lines

Almenara et al (2002)

Vorinostat+flavopiridol

Leukaemia (U937)

Kim et al (2003)

Vorinostat+VP-16, ellipticine, doxorubicin, or cisplatin

Human glioblastoma (D54), breast (MCF-7)

Nimmanapalli et al (2003)

Vorinostat+imatinib

Chronic myelocytic leukaemia (LAMA-84)

Rahmani et al (2003)

Vorinostat+Hsp90 antagonist (17-allylamino-17-demethoxygeldanamycin)

Human leukaemia (U937).

Marchion et al (2004)

Vorinostat+topoisomerase II inhibitors

Breast

Rundall et al (2004)

Vorinostat+NF-kappaB inhibitor (BAY-11-7085)

NSCLC (A549, H157, H358, H460, H1299)

Chinnaiyan et al (2005)

Vorinostat+radiation

Prostate (DU145) and glioma (U373vIII)

Ocker et al (2005)

Vorinostat+5-FU+irinotecan

Hepatoma (HepG2, Hep1B and MH-7777A)

Rahmani et al (2005)

Vorinostat+perifosine

Leukaemia (U937, HL-60 and Jurka)

Back to article page